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Background: Habit, a psychological process that automatically generates urges to perform a 
behavior in associated settings, is potentially an important determinant of medication adher-
ence. Habit is challenging to measure because, as a psychological construct, it cannot be 
directly observed. We describe a method of using routinely available objective adherence data 
from electronic data capture (EDC) to generate a behavior-based index of adherence habit and 
demonstrate how this index can be applied.
Methods to generate the habit index: Our proposed habit index is a “frequency in con-
text” measure. It estimates habit as a multiplicative product of behavior frequency (generated 
from weekly percentage adherence) and context stability (inferred from time of nebulizer use). 
Although different timescales can be used, we chose to generate weekly habit scores since we 
believe that this is the most granular level at which context stability can be reasonably calculated.
An application of the habit index: A hallmark of habit is to predict future behavior, hence 
we used time series method to cross-correlate the habit index with nebulizer adherence in the 
subsequent week among 123 adults with cystic fibrosis (52, 42.3% female; median age 25 years) 
over a median duration of 153 weeks (IQR 74–198 weeks). The mean cross-correlation coef-
ficient (R) between the habit index and subsequent adherence was 0.40 (95% CI 0.36–0.44). 
Adjusting for current adherence, the unstandardized regression coefficient (B) for the habit 
index was 0.30 (95% CI −1.04 to 1.65).
Conclusion: We have described a pragmatic method to infer “habit” from adherence data rou-
tinely captured with EDC and provided proof-of-principle evidence regarding the feasibility of 
this concept. The continuous stream of data from EDC allows the habit index to unobtrusively 
assess “habit” at various time points over prolonged periods, and hence the habit index may be 
applicable in habit formation studies.
Keywords: cystic fibrosis, medication adherence, nebulizers and vaporizers, habits
Introduction
Low medication adherence in long-term conditions is associated with worse health 
outcomes and higher health care cost,1–3 yet only around 50% of all medications are 
taken as recommended.4,5 In cystic fibrosis (CF) – a genetic long-term condition pre-
dominantly affecting the lungs and gastrointestinal tract – high adherence is associated 
with better health outcomes in terms of reduced pulmonary exacerbation risk, more 
stable lung function, reduced hospitalization risk, and reduced health care costs.6–10 
Efforts to improve medication adherence are therefore important to improve health 
outcomes, but various systematic reviews have shown that most adherence interven-
tions are not efficacious.11,12 Even efficacious interventions only have inconsistent or 
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short-term effects, with improved adherence not maintained 
beyond the intervention period.11,12
Interventions that effectively initiate behavior change 
may not necessarily sustain that change.13,14 A potential 
mechanism for sustaining behavior change is habit forma-
tion. Within psychology, the term “habit” describes a non-
conscious process by which a situational cue (eg, time of day) 
automatically generates an impulse toward enacting a behav-
ior (eg, taking medication), based on learned associations 
between the cue and the behavior.15 Habit associations are 
acquired when a specific behavior is repeated consistently in 
a specific setting.15 As habit develops, cognitive control over 
behavior shifts from reflective to automatic processes, such 
that encountering a contextual cue is sufficient to elicit the 
associated behavior, with little deliberation or forethought.15 
Behavior maintained by ongoing effortful self-control and 
conscious motivation would be susceptible to disruption 
when self-control is reduced; for example, during times 
of stress or if there is a need to devote resources to other 
cognitively effortful tasks.15 However, automatic control of 
habitual behavior reduces the dependency on conscious atten-
tion or deliberative processes, such that habitual behavior 
should persist even when attention or conscious motivation 
wane.16 Indeed, studies in various long-term conditions have 
highlighted the strong association between habit strength and 
medication adherence.17–23 A recent meta-analysis of 771 
trials also found medication adherence interventions that 
included habit formation were more effective than those that 
did not.24 Studies examining the association between medica-
tion adherence and habit rely on accurate measurements of 
habit, but measuring habit is challenging.
As a psychological process, habit cannot be directly 
observed, and so existing measures infer habit only 
indirectly. While lab-based tests exist eg, the Implicit 
Association Test,25 in the real-world habit is measured 
by self-report, predominantly using one of two types of 
measures. One involves self-reporting markers of habit. 
For example, the Self-Report Habit Index (SRHI)26 and 
its derivative, the Self-Report Behavioral Automatic-
ity Index (SRBAI),27 infer habit from reflection on the 
“symptoms” of habitual responding, such as lack of 
awareness, conscious intention, or control. Another 
involves reporting the frequency of previous behavior 
in a stable context to infer habit as a form of “frequency 
in context”,28 based on the assumption that “strong hab-
its” have been performed frequently in stable contexts 
whereas “weak habits” have been performed in unstable 
context or performed less frequently.29 The develop-
ment of self-reported habit measures has enabled the 
study of habit and allowed the role of habit to be better 
understood.30 For example, some of the seminal papers 
in habit are based on frequency in context measures.31,32
Nonetheless, the use of self-report to assess habit mea-
sures has been criticized.33,34 A think-aloud study has shown 
that people may misinterpret some of the SRHI items, or 
infer automaticity based on frequency of action (although the 
frequent behavior may have actually required considerable 
deliberative planning or cognitive effort).35 It is also argued 
that people’s recollection of behavior and experience is 
unreliable.33 A potential method of enhancing the frequency 
in context measure might be to bypass the subjectivity of 
self-report by using objective data for inferring behavior 
frequency and context stability.
Unlike habit, the behavior of using preventative inhaled 
therapy among adults with CF can be directly captured using 
electronic data capture (EDC), which is generally considered 
the “gold standard” method to capture adherence data.36 
In CF, tamper-proof intelligent nebulizer systems (I-neb®, 
Philips, Amsterdam, the Netherlands) which provide date- 
and time-stamped data for every dose of nebulized medica-
tion are routinely available.37 The I-neb® is a third-generation 
data-logging adaptive aerosol delivery system designed to 
optimize inhalation technique by directing flow and depth of 
inhalation, providing positive feedback signals to guide user, 
and only delivering aerosol when an inhalation of sufficient 
quality is detected.38 By routinely and accurately logging 
every episode of medication use (including date and time of 
use), both elements of a “frequency in context” measure, ie, 
“behavior frequency” and “context stability” (with time as a 
potential cue for nebulizer use, since previous studies have 
demonstrated that time of day is a useful cue for medication 
taking),39 are being captured. Thus, it may be possible to infer 
habitual responses (to time cues) using these objective data.
In addition to providing a truer reflection for both the 
actual frequency and time context of nebulizer use, the 
continuous stream of data from EDC also makes it feasible 
to unobtrusively assess “habit” at various time points over 
prolonged periods. EDC data are routinely available with-
out any additional effort from adults with CF (ie, data are 
automatically captured as long as nebulizer is being used). 
That means the habit index generated from EDC data would 
impose no additional burden on study participants, so would 
be more “participant-friendly” than administering multiple 
self-report items.
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In this paper, we aim to describe a pragmatic method of 
inferring “habit” from objective nebulizer adherence data and 
to demonstrate how this behavior-based index of adherence 
habit might be applied, using a predictive design to explore 
its relationship with subsequent adherence.
A description of our proposed behavior-
based habit index
This habit index is based on the format of a “frequency in 
context” measure. That means the proposed index is calcu-
lated by multiplying “behavior frequency” with “context 
stability”. Frequency in context measures is based on the 
theory that repetition in a consistent context leads to habit 
formation, and so more frequent repetitions (in a consistent 
context) and greater context stability (given equal number 
of repetitions) mean strongest likelihood of habit having 
formed, ie, represent strongest habit.
The method described in this paper would generate a 
weekly index in a linear 1–7 scale. This index could also be cal-
culated using different time periods (eg, fortnightly or monthly) 
or transformed linearly into different scales (eg, 0–100).
Calculating behavior frequency using 
adherence data captured by EDC
A behavior frequency score can be simply generated by 
converting weekly percentage adherence into a linear scale 
from 1.00 (adherence 0%) to 2.65 (adherence $100%). 
Using a 1–2.65 scale for “behavior frequency” score would 
result in a 1–7 habit index scale because the habit index is 
a product of “behavior frequency” and “context stability” 
(12=1; 2.652=7). This linear scale can be altered depending 
on preference. For example, a 1–100 habit index scale can 
be generated by using 1–10 scales for “behavior frequency” 
and “context stability”.
Calculating context stability using 
adherence data captured by EDC
The actual time of nebulizer use can be determined from 
date- and time-stamped EDC adherence data to infer “con-
text”. Stability/variability in context can be calculated as 
SD. An example of calculating variability in time of use is 
provided in Figure 1.
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Figure 1 An example to illustrate the calculation of SD as a measure of variability for the time of nebulizer use.
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In calculating the variability for time of use, it is impor-
tant to consider that adults with CF may use their inhaled 
preventative therapies in two separate sessions because 
inhaled antibiotics, eg, colistin and tobramycin, are meant 
for twice daily use, with the UK CF Trust recommending a 
minimum interval of 6 hours between doses.40 Both treatment 
sessions should be considered separately because behavior 
for one session may be discordant to the behavior in the other 
session (eg, adherence during “evening” sessions may be 
better compared to adherence during “morning” sessions41 
or vice versa). In considering the “morning” and “evening” 
sessions, using midnight–mid-day and mid-day–midnight 
scales is likely to be problematic. Many young people will 
go to bed after midnight, partly because the timing of mela-
tonin release shifts to a later time during adolescence.42 It is 
not uncommon for these “night owls” to use their inhaled 
therapy after midnight (eg, after returning from a night out). 
For example, a person may use his inhaled antibiotic at 10 am, 
and take the final dose of the day just before bed, which may 
on occasions be 1 am or 2 am. Using a 05:00–16:59 scale for 
the morning session and a 17:00–04:59 scale for the evening 
session may better reflect nebulizer use in the real world. 
Concordant sessions should be used to calculate variability 
in time of use, ie, morning sessions should be considered 
separate to evening sessions. Overall variability can then 
be calculated by applying weights relative to the number of 
sessions with $1 nebulizer use per week.
In calculating the variability for time of use, it is also 
important to consider that adults with CF may be using more 
than one dose of nebulizer in a single treatment session. For 
example, someone using nebulized colistin twice daily and 
dornase alfa once daily would be using a dose of colistin 
and a dose of dornase alfa in one of the two treatment ses-
sions. The time between both doses of nebulizer within the 
same session could be affected by other treatment routines, 
eg, chest physiotherapy. Therefore, only the time for the first 
nebulizer use of each session should be considered in calcu-
lating the variability in time of use. An example to illustrate 
that the calculation of variability in time of nebulizer use is 
based on SD is provided in Figure 2.
Following calculation of SD for time of nebulizer use as 
a variability measure, the context stability scores for time of 
nebulizer use can be generated by converting the variability 
measure into a linear scale from:
1. 1.00 (variability in time of use $180 minutes, ie, the 
maximum value), to
2. 2.65 (variability in time of use =0, ie, the minimum value).
If the nebulizer was not used at all in a week, the maxi-
mum variability value for time of use should be assigned 
(ie, 180 minutes), so that the minimum context stability 
score is generated to indicate minimal context stability. The 
same “penalty” should be applied if nebulizer use was too 
infrequent to calculate variability, since at least two separate 
values are needed to calculate SD.
In the example presented in Figure 2, the context stabil-
ity score based on SD as a measure of variability for time of 
nebulizer use would be:
 
= − = − =2.65 1.65
Variability
180
2.65 1.65
146.0
180
1.3











 1
Calculating the proposed behavior-
based habit index using adherence data 
captured by EDC
The proposed habit index (ranging from 1 to 7) is a product of 
“behavior frequency” (ranging from 1 to 2.65) and “context 
stability” (ranging from 1 to 2.65).
In the example presented in Figure 2, 20/21 doses of 
nebulizer were used during week beginning 06/01/2013. 
The adherence of 95.2% translates to “behavior frequency” 
score of 2.57. Therefore, the habit index for week beginning 
06/01/2013 would equate to 3.4 (ie, 2.57×1.31) for time of 
nebulizer use as the context.
An example application of the habit index
$KDOOPDUNRIKDELW²KDELWVWUHQJWKVKRXOGSUHGLFWWKH
performance of future behavior
A potential role of the proposed habit index is to predict 
future adherence, since a hallmark of habit measures’ predic-
tive validity is the relationship between habit strength and 
performance of future behaviors. For example, Ouellette and 
Wood demonstrated that self-reported “frequency in context” 
(ie, past behavior × context stability) is a stronger predictor of 
future television watching and recycling behaviors, compared 
to past behavior alone.43
For medication adherence, prolonged repetition of 
the behavior is required for health benefits to be realized. 
Empirical evidence suggests that health behaviors can be 
highly variable over time.44–47 Likewise, psychological pro-
cesses are also inherently variable over time.48,49 Thus, there 
is merit in studying the relationship between the behavior 
of using medication and psychological processes over the 
long term, to understand how this relationship changes 
over time. Adherence data that are routinely and accurately 
logged by EDC provide the opportunity to study the dynamic 
variability of the proposed habit index and adherence at a 
more granular level by using time series methods. Time 
series analysis refers to statistical methods used to analyze 
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
2.
31
.2
25
.2
05
 o
n 
13
-F
eb
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
Patient Preference and Adherence 2019:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
287
Hoo et al
Knnwuvtcvkxg"tcy"fcvc"htqo"K/pgd̶"vq"fgvgtokpg"xctkcdknkv{"hqt"yggm"dgikppkpi"28123135"*Uwpfc{+0
Kp"vjku"gzcorng."vjg"rgtuqp"ku"qp"qpeg"fckn{"fqtpcug"cnhc"cpf"vykeg"fckn{"eqnkuvkp0
Tgeqtf"pwodgt
3;59
3;5:
3;5;
3;62
3;63
3;64
3;65
3;66
3;67
3;68
3;69
3;6:
3;6;
3;72
3;73
3;74
3;75
3;76
3;77
3;78
3;79
3;7:
3;7;
Vkog
3:<45<63
32<28<76
36<53<43
39<52<52
3:<43<48
2:<63<65
38<79<7;
43<27<28
2:<56<76
42<57<65
44<46<54
2;<25<4:
43<46<47
45<3;<5;
2:<6;<36
38<2:<26
3:<64<44
2;<2;<6;
2;<38<3:
23<29<57
33<7:<24
35<44<24
34<32<74
Fcvg
2612314235
2712314235
2812314235
2812314235
2812314235
2912314235
2912314235
2912314235
2:12314235
2:12314235
2:12314235
2;12314235
2;12314235
2;12314235
3212314235
3212314235
3212314235
3312314235
3312314235
3412314235
3412314235
3412314235
3512314235
Fqug
Hwnn
Hwnn
Hwnn
Hwnn
Hwnn
Hwnn
Hwnn
Hwnn
Hwnn
Hwnn
Hwnn
Hwnn
Hwnn
Hwnn
Hwnn
Hwnn
Hwnn
Hwnn
Hwnn
Hwnn
Hwnn
Hwnn
Hwnn
Fwtcvkqp"*okpwvgu+
7
4
7
4
6
5
5
6
7
4
5
5
7
5
5
5
6
5
4
7
4
5
32
Vjg"ogvjqf"vq"yqtm"qwv"vjg"xctkcdknkv{"hqt"vkog"qh"wug<
Vkog"qh"wug"*yggm"dgikppkpi"28123135+<
Fcvg
28123135
29123135
2:123135
2;123135
32123135
33123135
34123135
ÐOqtpkpiÑ"*27<22Î38<7;+
36<53<43
2:<63<65
2:<56<76
2;<25<4:
2:<6;<36
2;<2;<6;
33<7:<24
ÐGxgpkpiÑc"*39<22Î26<7;+
27<52<52
2;<27<28
2:<57<65
2;<46<47
28<64<44
35<29<57d
P1C
Uvcpfctf"fgxkcvkqp"*UF+<
Oqtpkpi"uguukqp"?"35804"okpwvgu
Gxgpkpi"uguukqp"?"37906"okpwvgu
Ygkijvkpi<"Oqtpkpi"?"9"uguukqpu
Gxgpkpi"?"8"uguukqpu
Qxgtcnn"UF"? *35804'9+"-"*37906'8+9-8 ?"36802"okpwvgu
Figure 2 An example to illustrate the calculation of SD for time of use in someone using nebulizer over two sessions.
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on the software used. For example, in someone who uses nebuliser at 23:45, 23:55, 00:15 and 23:52, the difference between 00:15 and 23:55 could be miscalculated as 
KRXUVDQGPLQXWHV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treatment for 11/01/2013.
Abbreviation: NA, not available.
time-ordered serial measurements, and it can be used to 
predict future behaviors, explain characteristics of behaviors, 
and understand factors influencing the behaviors.50,51 We 
therefore set out to determine the cross-correlation between 
the proposed behavior-based habit index and subsequent 
nebulizer adherence.
Methods
Design and setting
Data were drawn from a single-center retrospective observa-
tional study. All adults with CF diagnosed according to the 
UK CF Trust criteria52 in Sheffield, UK, aged $16 years, and 
using I-neb® as part of their routine treatment were included, 
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except those with lung transplantation or on ivacaftor. Both 
lung transplantation and ivacaftor have transformative effects 
on lung health,53–55 such that their treatment requirements 
may no longer represent that of a typical adult with CF.56,57
All I-neb® data for a calendar year period were excluded 
if there was no nebulizer use for .24 consecutive weeks 
or for .90% of the time period on I-neb® (eg, 24 weeks of 
I-neb® data available but nebulizer was only used in two of 
those weeks). This data exclusion is to avoid spurious cross-
correlation between the behavior-based habit index (which 
will be at the minimum score of “1” if I-neb® was not being 
used) and nebulizer adherence (which will also be at the 
minimum score of “0” if I-neb® was not being used). This 
study was approved by the NHS Health Research Authority 
(IRAS number: 210313). This study was carried out in accor-
dance with the principles of the Declaration of Helsinki. All 
participants provided written informed consent for the analy-
sis of their routinely collected clinical and adherence data.
Data collection and processing
Clinical data including age, gender at birth, %FEV
1
, and 
nebulizer prescription details were extracted by two inves-
tigators independently reviewing paper notes and electronic 
records. Nebulizer adherence data were downloaded from 
I-neb®. Adherence was calculated as a percentage of total 
nebulizer doses taken against the agreed dose between clini-
cians and adults with CF. Based on this method of quantifying 
adherence, adherence levels can vary from 0% to .100% 
(due to potential nebulizer overuse), with higher adherence 
being more desirable although nebulizer adherence .100% 
may not be optimum (this may vary with the medications – 
hypertonic saline may be beneficial if used more frequently 
whereas antibiotics may cause toxicity if used substantially 
more frequently than the prescribed doses).
Weekly behavior-based habit index, which can vary from 
1 (ie, weakest habit) to 7 (ie, strongest habit), for each study 
participant was generated from I-neb® data with methods as 
described in the “a description of our proposed behavior-
based habit index” section by using a pre-programmed 
Microsoft Excel v.2010 (Microsoft) spreadsheet. “Context 
stability” was inferred from time of nebulizer use, and vari-
ability in context was calculated using SD.
Data analysis
Analyses were performed using SPSS v24 (IBM Corpora-
tion). Each weekly habit index from each study participant 
was cross-correlated with percentage adherence at the 
subsequent week using a linear regression model with time-
ordered habit index as a single covariate and adherence as 
the dependent variable (ie, habit index at Week 1 correlated 
with adherence at Week 2, habit index at Week 2 correlated 
with adherence at Week 3, and so on). This method models 
the trends of weekly habit index and adherence as linear func-
tions of time49 but does not account for autocorrelation in the 
data,58 meaning that the resultant cross-correlation coefficient 
will conflate both the genuine (changes in adherence that are 
actually related to prior changes in habit index) and spurious 
(independent changes of both habit index and adherence with 
time) associations between these two time-ordered variables.
Therefore, multiple regression was also performed for 
each study participant using both time-ordered habit index 
and current adherence as the covariates, with subsequent 
percentage adherence as the dependent variable. Using 
both habit index and percentage adherence as the covariates 
achieved two important functions. First, autocorrelation is 
removed from adherence data, ie, the genuine association 
between the habit index and subsequent adherence can be 
determined. Second, it controls for present adherence. This 
is crucial because nebulizer adherence among adults with 
CF is an ongoing behavior (ie, behaviors that have been 
performed many times and are still continuing). Correlation 
of a psychological construct with an ongoing behavior will 
conflate both the effect of the psychological construct on 
behavior and the effect of behavior on the psychological 
construct.59 By controlling for present behavior, bias from 
the effects of behavior on the psychological construct is 
mitigated; that is, the resultant correlation coefficient will be 
a purer measure of the effect of the psychological construct 
on behavior.59
Following time series analyses of individual data, the 
individual results were aggregated and analyzed at a group 
level. Appropriate descriptive statistics were generated, with 
both the effect sizes and CI for the habit index–adherence 
associations being reported. Both the correlation coefficients 
(R) for the habit index–adherence association from univari-
ate linear regression and unstandardized coefficients (B) for 
the habit index from multiple regression were also strati-
fied according to stability of adherence. This is to explore 
whether habit index–adherence associations were influenced 
by different adherence patterns. The three a priori adher-
ence patterns of interest are 1) people with consistently low 
adherence (ie, all 3-monthly adherence sections of #25%), 
2) people with consistently high adherence (ie, all 3-monthly 
adherence sections of .75%), and 3) everyone else with 
varying adherence. The use of 3-monthly adherence sections 
and the #25%/ .75% thresholds to understand whether 
adherence is changing over time are based on an adherence 
clustering algorithm that was previously published.60
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
2.
31
.2
25
.2
05
 o
n 
13
-F
eb
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
Patient Preference and Adherence 2019:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
289
Hoo et al
Results
This analysis included 123 out of 126 adults with I-neb® 
data. Data for three adults who only had minimal nebulizer 
use were excluded (Person 1: adherence 0.2% over 39 
weeks; Person 2: adherence 8.7% over 47 weeks; Person 3: 
adherence 2.3% over 22 weeks). Of the 123 included adults, 
52 (42.3%) were females. The median age of this cohort was 
25 years (IQR 19–31 years) and median %FEV
1
 was 74.0% 
(IQR 54.9%–87.5%). Median adherence of the cohort was 
47.3% (IQR 26.2%–76.4%), with median data duration of 
153 weeks (IQR 74–198 weeks). Most of the adults (99/123, 
80.5%) had variable adherence. An example of adherence 
time series graph along with the habit index superimposed on 
the graph for a person with variable adherence is presented 
in Figure 3.
The mean cross-correlation coefficient between the habit 
index and subsequent adherence was 0.40 (95% CI 0.36–
0.44) for the entire cohort (Table 1). However, those with 
variable adherence displayed higher mean cross-correlation 
coefficients (mean 0.45) compared to those with consistent 
adherence (mean 0.20–0.24).
By including both the habit index and current adherence 
as the covariates in a multiple regression, the regression 
coefficient (B) for habit index was small (mean 0.30; ie, 
1 unit increase in the habit index was associated with a 0.3% 
increase in the subsequent week’s adherence, after control-
ling for current adherence). The 95% CI also included nega-
tive values (−1.04 to 1.65; ie, increase in habit index may 
be associated with decline in subsequent week’s adherence, 
after controlling for current adherence) (Table 2).
Part of the higher cross-correlation coefficient for the 
habit index–subsequent adherence association among people 
with variable adherence was due to autocorrelation in adher-
ence data. After removing the autocorrelation in adherence 
data with the multiple regression analysis, those with variable 
adherence had the lowest regression coefficient (mean 0.08, 
95% CI −1.44 to 1.60).
Discussion
We have described a pragmatic method of inferring “habit” 
for the behavior of using nebulizer and demonstrated the 
feasibility of generating weekly habit index among a cohort 
of 123 adults with CF over a median period of 153 weeks. 
We were able to evaluate the habit index over a prolonged 
period because health care for people with CF is almost 
exclusively delivered by multidisciplinary teams through 
specialist CF centers, hence loss to follow-up is unlikely to 
occur. In addition, this is an observational study utilizing 
routinely collected data without burdensome additional data 
collection. The habit index was generated from routinely 
Figure 3 Illustrative habit index (generated from time of nebulizer use) and adherence time series graphs.
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collected I-neb® data, and an I-neb® typically stores 3,000–
4,000 datapoints.37
Habit is an automatic process by which behavior is con-
textually cued.15 As habit forms through associative learning 
during context-dependent repetitions, cognitive control of a 
behavior shifts from reflective to automatic processes, which 
reduce the dependence of habitual behaviors on conscious 
attention or deliberative processes.15 Habitual behavior 
should therefore persist even if attention or conscious 
motivation wane, ie, habit can shield new behaviors from 
relapse and determine behavior frequency.15 We provided an 
example of applying the habit index to study its association 
with subsequent nebulizer adherence. Treatment regime for 
a person with CF typically consists of multiple components 
due to the multisystem nature of CF. A similar habit index 
could be generated for other treatment modalities (or even 
medications for other long-term conditions) in which time-
stamped EDC data are available, such as Medication Event 
Monitoring System for oral medications, eg, pancreatic 
enzyme replacement therapy or chipped physiotherapy 
adjuncts. Using data from intelligent nebulizers (I-neb®), we 
found a mean cross-correlation coefficient of 0.40 between 
the “habit scores” and nebulizer adherence in the following 
week. This is comparable to the average correlation coef-
ficient (0.39–0.53) shown in previous research between the 
dominant self-report habit measure (the SRHI) and a range 
of health behaviors.27,61
A study looking at the habit of using asthma medications 
found a larger correlation coefficient of 0.61 between SRHI 
and adherence.18 However, it is important to interpret these 
coefficients in the context of the analysis method. Previous 
studies have only compared habit strength against behavior 
using measurements at one to three time points,18,27,61 whereas 
we cross-correlated habit index against subsequent adherence 
at multiple time points using time series analysis. Time series 
methods allow the relationship between habit and behavior to 
be studied at a more granular level (eg, week-by-week rela-
tionships can be studied instead of just using measurements 
at one or two time points) and directionality of relationships 
to be evaluated (habit strength can be cross-correlated with 
subsequent adherence to understand how prior changes in 
habit relate to subsequent changes in adherence).49 Cross-
correlation using time series methods for time-ordered data 
at multiple points will typically yield lower coefficients com-
pared to correlation coefficients compared at only a few time 
points. For example, correlation of previous nebulizer adher-
ence measured on an annual basis (ie, adherence measured 
at a “single time point”) against subsequent annual nebulizer 
adherence using the Sheffield dataset yielded correlation 
coefficients of 0.82 (95% CI 0.73–0.88) for 2013–2014 
(n=79 pairs of measurements); 0.84 (95% CI 0.76–0.89) for 
2014–2015 (n=92 pairs); and 0.85 (95% CI 0.78–0.90) for 
2015–2016 (n=93 pairs). Such high correlation coefficients 
were obtained by comparing annual adherence despite clear 
year-on-year improvement of adherence from 43.6% in 2013 
to 55.1% in 2016 as previously reported.62 In contrast, cross-
correlation of time-ordered adherence data against adherence 
in the subsequent week (ie, lag 1 autocorrelation) among the 
123 study participants included in this analysis only yielded 
a mean coefficient of 0.51 (95% CI 0.47–0.55).
After controlling for current behavior (by performing 
multiple regression of time-ordered habit index and current 
adherence as the covariates), the proposed habit index was 
found to have little effect on subsequent adherence (mean 
unstandardized coefficient of 0.3). This is in part because 
controlling for present behavior would underestimate the 
effects of psychological construct on subsequent behavior.59 
The strong correlation between past and future behaviors is 
also well recognized.43,63,64 Studies using self-report measures 
Table 1 7KH FURVVFRUUHODWLRQ FRHIÀFLHQWV R) for the habit 
index and subsequent adherence
Adherence type Habit index cross-correlation 
FRHIÀFLHQWPHDQ&,
Overall cohort (n=123) 0.40 (0.360.44)
Adherence consistently 
low, ie, #25% (n=6)
0.24 (0.040.44)
Variable adherence (n=99) 0.45 (0.410.49)
Adherence consistently 
high, ie, .75% (n=18)
0.20 (0.130.27)
Table 2 7KH XQVWDQGDUGL]HG UHJUHVVLRQ FRHIÀFLHQWV B)a for 
the habit index, using time-ordered habit index and current 
adherence as the covariates with subsequent adherence as the 
dependent variable in a multiple regression
Habit index unstandardized 
FRHIÀFLHQWPHDQ&,
Overall (n=123) 0.30 (−1.04 to 1.65)
Adherence consistently low, 
ie, #25% (n=6)
3.03 (−9.68 to 15.76)
Variable adherence (n=99) 0.08 (−1.44 to 1.60)
Adherence consistently high, 
ie, .75% (n=18)
0.61 (−1.90 to 3.13)
Note: a$UHJUHVVLRQFRHIÀFLHQWRIPHDQWWKDWXQLWLQFUHDVHLQWKHKDELWLQGH[
ZKLFKFDQYDU\IURP>LHZHDNHVWKDELW@WR>LHVWURQJHVWKDELW@ZDVDVVRFLDWHG
ZLWKDLQFUHDVHLQWKHVXEVHTXHQWZHHN·VDGKHUHQFHZKLFKFDQYDU\IURP
to .100%).
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have also tended to find higher correlation between behaviors 
and habit measures which included behavior frequency. For 
example, the validation study for SRBAI (an automaticity 
subscale of SRHI) found higher correlation between behavior 
and SRHI (which included items of behavior frequency), 
compared to SRBAI (which only included automaticity 
items).27 An unpublished study included both behavior 
frequency × context stability (BFCS) scores (a frequency in 
context self-report measure) and SRHI scores in a multiple 
regression model, and found that only BFCS scores explained 
significant variance in behavior.29
Although past behavior does predict future behavior, 
studying a behavior by just using previous behavior as a 
proxy for habit lacks explanatory value as to why the behavior 
was enacted or how it might change in the future. Therefore, 
developing an adequate habit measure remains important. By 
demonstrating the association between our proposed habit 
index and subsequent adherence using time series analysis, 
we have highlighted that the index can potentially track how 
habit changes over time. The habit index may be applicable 
in habit formation studies. For example, it might be used in 
a study investigating the development of habit to understand 
how long it takes to form the habit of using nebulizer, or to 
investigate fluctuation in habit over time.
We nonetheless acknowledge the limitations of inferring 
“habit” from EDC adherence data. For example, “habit” 
would be inferred as “absent” when a behavior was not 
enacted. Yet habit is not behavior, so it is possible that some-
one may have a habit that they are not acting on, for whatever 
reason.15 As a form of frequency in context measure, the pro-
posed habit index also assumes a compensatory relationship 
between behavior frequency and context stability (ie, frequent 
behavior in varying settings is expected to have the same 
influence on habit strength as infrequent behavior in unvary-
ing setting), but this assumption is untested. Existing EDC 
adherence data lack contextual information other than time of 
use. Any feature in the environment including (but not limited 
to) locations, presence of other people, and prior responses 
in a sequence of actions can cue a behavior.15 Although the 
exact time of day (eg, 7 am) can act as a contextual cue for 
medication adherence,39 it may be that prior action (eg, after 
brushing teeth in the morning) is a more relevant contextual 
cue to instigate nebulizer use among adults with CF. Some 
activities are nonetheless time sensitive (eg, people watching 
the 10 pm news would do so at 10 pm), while other activities 
(eg, waking from sleep) may recur every 24 hours, though the 
actual time may vary (eg, among shift workers). As technol-
ogy advances, it is likely that EDC in the future will capture 
more contextual information. Advances in sensor technology 
has allowed the development of “context-aware” reminder 
systems to support behavior change, ie, reminders that are 
only triggered in the appropriate environmental settings.65–67 
These sensors could potentially be used to capture extensive 
contextual information related to enactment of behavior, 
eg, setting/location in which behavior is enacted, prior 
actions, and presence of other people. As these technologies 
become ubiquitous, it may be possible to infer “habit” using 
a range of such contexts for different individuals (ie, tailor 
the “habit” measure according to idiosyncratic context cues 
that activate impulse toward behavior).
Regardless of the contextual information available, there 
is uncertainty regarding the optimal method to measure 
context stability. We chose to measure context stability on a 
weekly basis because that is the most granular level at which 
the habit index can be generated, and studying the habit index 
at the most granular level, in theory, allows earlier detection 
of behavior change. However, it might be that a behavior 
needs to be observed over a longer period of time in order 
to infer “stable habit” from that behavior. Non-performance 
of a behavior does not necessarily imply habit has changed, 
but missing the opportunity to enact a behavior or a slight 
change in routine would alter the proposed habit index if it 
were being inferred from behaviors over a short time dura-
tion. It is uncertain how quickly habit strength for nebulizer 
use among adults with CF changes over time. A previous 
study modeling habit formation for a new healthy eating, 
drinking, or exercise behavior found that the median time 
for habit strength (measured with 7 out of 12 items from 
the SRHI) to plateau was 66 days.68 However, there was 
considerable variation between individuals (range for the 
cohort was 18–254 days) and between behaviors (longer 
time for exercise behavior compared to healthy eating or 
drinking), though, potentially due to small sample size, the 
difference was not statistically significant.68 If variability 
was being measured over a fixed time period (ie, the method 
that we have proposed), frequency of behavior would influ-
ence the number of readings available to calculate the index 
of variability. For example, SD for time of nebulizer use 
could only be calculated from two readings if someone 
only used nebulizer in two sessions of that week, whereas 
seven readings will be available to calculate SD in someone 
who used nebulizer in all seven sessions of that week. SDs 
may be influenced by the number of readings available. If 
there were only a few readings, spuriously low (or high) 
SD values may be obtained. In the example we presented 
in Figure 3, there was a small increase in the habit index 
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despite quite substantial rise in adherence, in part because 
variability in time of nebulizer use for that person increased 
when the nebulizer was being used more frequently. This 
might reflect that use was not habitual, or that time is not 
the contextual cue for habitual nebulizer use for that person, 
or that the method to measure variability was insufficiently 
sensitive and requires improvement. An alternative method 
to determine the “context stability” score would be to use a 
fixed amount of data in calculating variability (eg, calculate 
SD for every seven sessions of nebulizer use, regardless of 
when these sessions occur). However, this means the habit 
index could only be calculated infrequently for people with 
low adherence. This might not matter if habit tends not to 
fluctuate over short time periods. In terms of the variability 
index itself, different methods can be used to calculate vari-
ability including coefficient of variation (ie, ratio of the SD to 
the mean),69 “median deviation” (ie, the difference between 
the maximum and median value),70 or sigma (which signifies 
variation-over-time and is calculated from moving ranges).71 
Our previous analyses found little difference between SD, 
“median deviation”, or sigma (data not shown). In theory, 
sigma accounts for time order in data dispersion71 and may be 
the most suitable index of variability for this purpose. There is 
also uncertainty regarding the limits for variability indices in 
the calculation of “context stability” scores (eg, variability in 
time of nebulizer use of $180 minutes was assumed to infer 
minimum “context stability”). Due to these methodological 
uncertainties, further exploration using a larger dataset could 
potentially model the fluctuation of “context stability” over 
time to further refine the habit index.
There are also limitations with available methodologies 
to evaluate a habit index inferred from EDC adherence 
data. There is no “gold standard” habit measure to validate 
the habit index. Using a “less correct” measure (eg, any of 
the self-report habit measures) for validation72 is feasible. 
However, it would not be possible to determine whether 
differences between the habit index and a self-report habit 
measure is due to the habit index lacking validity, or the 
self-report habit measure lacking validity, or a combination 
of both. Since the hallmark of habit measures’ predictive 
validity is to predict the likelihood or frequency of future 
behavior’s enactment,15 we determined the correlation 
between the proposed habit index and subsequent adherence. 
It could be argued that using the same dataset to generate 
and then to evaluate the habit index would inflate the asso-
ciation between “habit” and adherence. However, habit “at 
baseline” was being correlated with subsequent adherence, 
ie, identical data were not being correlated. It is nonetheless 
recognized that correlating a psychological construct with a 
behavior using observational data would conflate effects of 
behavior on the psychological construct as well as effects 
of the psychological construct on behavior, especially for 
ongoing behaviors.59 Controlling for current behavior (eg, by 
performing multiple regression of time-ordered habit index 
and adherence as the covariates in our analysis) helps to miti-
gate against bias from the effects of behavior on perception.59 
However, we acknowledge that our analysis is not a definitive 
test for the proposed habit index, and further validation work 
is required. This is ideally carried out using an experimental 
design (eg, studying habit formation in randomized clinical 
trials whereby the construct of interest is prespecified and 
mediational analyses were conducted to determine whether 
the construct served as a vehicle of change), since this type 
of study yields the least ambiguous cause–effect conclusions 
and offers opportunities to establish causality.59
Developing an adequate habit measure is important 
to better understand the relevance of habit to medication 
adherence. We have described a method of inferring a 
habit index from routinely available objective nebulizer 
adherence data among adults with CF and provided an 
example of how the habit index can be applied to study 
the relationship between habit and medication adherence. 
There is uncertainty regarding the optimal method to infer 
context stability, and further validation of the proposed habit 
index is required. Current EDC data also lack sufficient 
contextual information about the behavior, although context 
stability can potentially be inferred more reliably with the 
advent of better context-sensing technology. This may be a 
promising avenue to further explore in terms of developing 
useful habit measures, since there is no method to directly 
measure habit impulse.
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